Pfizer, Express Scripts Clash Over Biosimilar Formulary Placement
Executive Summary
Pfizer VP blames rebate strategies of innovators for difficulty in getting biosimilars on formularies while Express Scripts official says it is all about net cost during House hearing on lowering Rx drug prices.
You may also be interested in...
FTC Wades Into ‘Rebate Walls’ And Biosimilar Access With Remicade Investigation
Investigation may help define when rebate arrangements seeking to protect a brand against biosimilar competition are anticompetitive.
Sharing Biosimilar Savings With Physicians Could Boost Market Share Over 50%, Trade Group Says
But even with the legislative and regulatory changes proposed by the Biosimilars Forum, market share would still not reach levels seen in Europe, an analysis by Avalere finds.
Amgen Resolves Repatha Access Kerfuffle With Express Scripts
On eve of congressional hearing, the pharmacy benefit manager assures Amgen that Repatha is available to its employees.